HAS Group unveils a CHF 100 million investment plan to expand CDMO capacity and enhance ADC and HPAPI technologies, consolidating its leadership in the sector and supporting future growth.
HAS Healthcare Advanced Synthesis Group has announced an ambitious strategic investment plan aimed at further strengthening its position as a leading CDMO, one year after the merger between HAS and Cerbios. The new industrial roadmap, supported by solid results and successful integration, includes over CHF 100 million in investments across its Biasca and Lugano sites.
The five-year plan focuses on expanding production capacity in key CDMO areas and broadening the technological offering for partners and clients. A particular emphasis is placed on enhancing activities related to ADCs (Antibody-Drug Conjugates), one of the most promising therapeutic platforms in oncology and other high-value fields.
Key initiatives include strengthening HPAPI capabilities and expanding ADC conjugation lines. A new large-scale conjugation line of up to 500 liters is scheduled to become operational in May 2026, followed by a second 500-liter commercial line in early 2028. Meanwhile, the Biasca site will be further upgraded to support commercial ADC production, accompanying client launches and fostering long-term collaborations.
To sustain this growth, the Group has already hired over 30 highly qualified professionals in technical, scientific, and managerial roles, with additional recruitment planned throughout 2026. The stated goal is to consolidate a CDMO model capable of supporting clients from early development through to commercial production, ensuring quality, safety, and competitive timelines.
With this plan, HAS Group reaffirms its vision as a strategic partner for the development and manufacturing of high-tech solutions, strengthening its role in the international landscape of advanced therapies.
HAS Healthcare Advanced Synthesis
